Trial Profile

A Phase II Study of the Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib, and Dexamethasone Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 20 Apr 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bortezomib (Primary) ; Dexamethasone (Primary) ; Lenalidomide (Primary)
Indications Multiple myeloma
Focus Therapeutic Use
Acronyms RsqVD

Most Recent Events

18 Apr 2022 Results of two phase 2 studies (CTI; NCT02219178 & DFCI; NCT02441686) were published in the American Journal of Hematology.
16 Jul 2020 Status changed from active, no longer recruiting to completed.
26 Jul 2019 Planned primary completion date changed from 1 Nov 2018 to 1 Oct 2019.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com